Fair Value Measurements - Narrative (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Aug. 10, 2026 |
Apr. 21, 2026 |
Sep. 30, 2026 |
Sep. 30, 2026 |
|
| Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
| Contingent consideration | $ 383,000 | $ 383,000 | ||
| Royalties | ||||
| Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
| Contingent consideration | 248,000 | 248,000 | ||
| Kashiv Biosciences, LLC | ||||
| Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
| Contingent consideration | $ 350,000 | $ 350,000 | 383,000 | 383,000 |
| Contingent payments | $ 0 | $ 0 | ||
| Kashiv Biosciences, LLC | Royalties | ||||
| Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
| Potential contingent payments (percent) | 25.00% | |||
| Eligibility period | 12 years | 12 years |